At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed Nov 13, 2026 at 17:10 ET
IM Cannabis reported Q3 2026 revenue of C$1.65M, down 68% from C$5.08M a year ago, and a net loss of C$7.08M versus a C$3.87M loss in Q3 2025. The results reflect the sale of European operations (Adjupharm GmbH) and a focus on Israeli medical cannabis, with a non-binding agreement to acquire a 51% stake in a Polish drone company (SDI).
- Q3 2026 revenue C$1.65M vs C$5.08M in Q3 2025 (down 68%)
- Q3 2026 net loss C$7.08M vs C$3.87M in Q3 2025 (loss nearly doubled)
- Gross loss of C$35,000 in Q3 2026
- First nine months 2026 revenue C$8.96M vs C$15.77M (down 43%)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access